Latest filingSep 24, 2026Most recent Form 4
ENGN
enGene Therapeutics Inc.
NasdaqHealthcareBiological Products, (No Diagnostic Substances)
Insider activity for last month from 08/25 to 09/25. Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.
Total buying$10.0k1 buys
Total selling$00 sells
Net open-market+$10.0k1 insiders
Open-market mix
Buy vs sell distribution by transaction countInsider activity report
Monthly purchases, sales and code-A awards Buys Sells Awards / grants (A)
Code A includes awards, grants and other acquisitions; these are not open-market buys.
Distinct insiders active
Reporting-owner CIKs by month · peak Sep 2026 (1)Aug 2026Sep 2026
Top insiders
By absolute net value across the selected period- GW+$10.1k
Recent filing activity
Most recent 1 transactions · color = transaction code- PBuy09/24$10.0kSEC
Filing detail checks
Secondary metrics for the selected periodTransaction codes
By Form 4 transaction code in selected period1transactionstxns
- P · Open-market buys · dominant1 · 100%
Activity by reported role
A joint filing can contribute to multiple roles1transactionstxns
- ICMO · dominant1 · 100%
Reported Holdings After
Separated by insider, security, and ownership type
Grossman WilliamCommon Shares · Direct
5,102Sep 22, 2026
These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.
Filing activity heatmap
Each cell is one day · intensity = transactions · buys green, sells redAug 25 → Sep 25
LessMore
Filing-only signals
Deterministic matches in the selected period
No filing-only signal badges matched this period.
ENGN transaction history
Filters apply within this company and selected period by defaultLatest insider transactions
Form 4 filings from last month. Click any column to sort; click it again to flip the order.
enGene Therapeutics Inc. Insider Activity FAQ
SEC Form 4 contextWho recently reported transactions at enGene Therapeutics Inc.?
Grossman William.
When was the latest reported open-market purchase?
Grossman William reported a buy on Sep 22, 2026 valued at $10.0k. Read the SEC filing.
When was the latest reported open-market sale?
No code-S sale is available for this period.
What is the recent purchase and sale balance?
Net open-market buying in the selected period was $10,050.94. This describes filed transactions, not a bullish rating.
Where can I see the original SEC filing?
Every transaction row and latest-activity fact links to its original SEC filing.
What do these Form 4 transaction codes mean?
P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.